People's Daily health client reporter Tan Qixin
According to the latest announcement of the National Health Commission, on April 5, more than 20,000 new cases of local COVID-19 positive infections were added to the mainland, setting a new high for this round of epidemics. Since March 12, the number of new indigenous infections on the mainland has exceeded 1,000 consecutive daily, which is also the highest number of new infections since the outbreak of the new crown pneumonia epidemic in China at the end of 2019.
The reporter combed and found that the Aomi Kerong variant strain was first imported into hong kong on November 27, 2021, and was first imported into tianjin on december 9, 2021. Subsequently, many places have been punctate infections, and the wave of Infection in Rio Mikrong has spread in Jilin and Shanghai in the past month or so.
Workers at the Chinese Center for Disease Control and Prevention received strains of the new coronavirus for vaccine production that arrived from Zhejiang. Xinhua News Agency, Liu Peicheng/Photo
Strengthen vaccination and consolidate the "first line of defense" against the epidemic
"As the most powerful technical means to control infectious diseases, the new crown vaccine is still the most effective measure to deal with the normalization of epidemic prevention and control." Zhang Boli, an academician of the Chinese Academy of Engineering, said in an interview with the People's Daily health client reporter.
In order to control the spread of various variants and the spread of the new crown pneumonia epidemic, all countries are actively carrying out large-scale intensification of COVID-19 vaccines to consolidate the "first line of defense" against the epidemic. Among them, the United States, the United Kingdom and other countries have taken the lead in implementing the sequential strengthening of immunization strategies with different technical routes.
The reporter combed and found that data from many countries showed that strengthening immunization has significantly improved the absolute protection of Omicron (relative to the protection of unvaccinated people). On 9 March, The New England Journal of Medicine published data from real-world research from Qatar showing that the 3rd dose of Modena vaccine after 2 doses of Modena vaccine based immunization sequentially strengthened the relative protection against symptomatic infections in Omiqueron with 47.3%. Data from real-world studies from the UK, also published in the New England Journal, showed that in subjects who received the adenovirus vaccine (AstraZeneca) as the basic immunity, the absolute protection of the vaccine was 62.4% 2 to 4 weeks after the intensive sequential vaccination of 1 dose of mRNA vaccine (Pfizer).
Data from real-world research in the United States, published in nature medicine (a sub-issue of nature magazine), show that the absolute protection of 3 doses of mRNA vaccine (Modena) against Aumechjong infection is 62.5%.
The domestic vaccine under research has a prominent protection rate of the successive strengthening of the Aomi Kerong, and the absolute protective power can reach 61.35%
According to the Data of the State Food and Drug Administration, as of now, 5 domestically produced new coronavirus vaccines have been approved for use in the mainland. Including 3 inactivated vaccines produced by Sinopharm Zhongsheng Beijing Company, Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company, the type 5 adenovirus vector vaccine produced by Tianjin CanSino Company, and the recombinant novel coronavirus vaccine (CHO cells) of Zhifei Bio.
At the same time, three domestic vaccines are already in the critical clinical stage, namely the mRNA vaccine of Watson Bio/Aibo Bio, the recombinant protein vaccine of Clover/CEPI/Dynavax, and the new crown vaccine V-01 of Livizumab. Among them, the new crown vaccine V-01 of livlotumab has entered the phase III clinical trial stage.
"At present, the basic immunization of inactivated seedlings in China has been basically completed, and studies at home and abroad have shown that the sequential enhancement of immunization on the basis of inactivated seedlings is the most powerful measure to improve the protective effect on Omicron and other future epidemic strains." On April 5, Dr. Yang Jiaming, executive deputy general manager of Livzon Biologics, revealed in an interview with the People's Daily health client reporter that livzonumab's new crown vaccine V-01 has recently completed the interim main data analysis of the sequential strengthening phase III clinical trial and obtained key data.
The results of its latest phase III clinical key data analysis show that on the basis of 2-shot inactivated seedlings, the absolute protective power of V-01 against infections with mild symptoms and above (relative to the protective power of unvaccinated people) after sequential strengthening is 61.35%, and the high-risk population with underlying diseases is as high as 71.83%, which is equivalent to the homologous or heterologous 3-shot enhancement effect of foreign Pfizer and Modena mRNA vaccines, and the enhanced effect is outstanding compared with the 3-shot enhancement effect of inactivated vaccines. With a low rate of adverse reactions (comparable to that of the placebo group), it is currently the only sequential vaccination against the Opichron variant supported by protective phase III clinical data.
When will the V-01 sequential booster vaccine be used in China? "We have submitted the V-01 Sequential Enhancement Phase III Clinical Report and Conditional Listing Application Data to the National Drug Review Center on February 18, and the results of the key data analysis of phase III clinical data were also submitted recently. At present, our stock solution production capacity can reach 3.5 billion doses / year, preparation production capacity of 1.5 billion doses / year, and strive to be approved for use as soon as possible at the current critical moment of national epidemic prevention. Yang Jiaming told reporters.